🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. INDOCYANINE GREEN

    Disc Medicine

    cervical cancer stage I-IIA

    approved small molecule active

    1 trial

  2. Ibrutinib

    AbbVie Deutschland GmbH & Co. KG

    1. Follicular Lymphoma 2. Chronic Lymphocytic Leukemia 3. Waldenstrom macroglobulinemia 4. Multiple Myeloma 5. Marginal Zone Lymphoma 6. Diffuse Large B-Cell Lymphoma 7. Urothelial Carcinoma 8. Breast Cancer 9. Acute Myeloid Leukemia 10. Graft vs Host Disease 11. Mantle Cell Lymphoma

    approved small molecule active

    1 trial

  3. Ilaprazole

    Yang Xiaotian

    Gastric Cancer

    approved small molecule completed

    1 trial

  4. Jejunostomy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    approved other active

    1 trial

  5. KANG FU PEN

    The First People's Hospital of Lianyungang

    Cervical Cancer

    approved small molecule active

    1 trial

  6. LETROZOLE, RIBOCICLIB, GOSERELIN ACETATE, LEE011, TAMOXIFEN

    Novartis Pharmaceuticals

    HR+, HER2- advanced or metastatic breast cancer

    approved small molecule active

    1 trial

  7. LORLATINIB

    Pfizer Australia Pty Ltd

    Lung cancer

    approved small molecule active

    1 trial

  8. Lutrate Depot Trimestral 22,5 mg polvo y disolvente para suspensión inyectable de liberación prolongada, Verzenios 150 mg film-coated tablets, Femara 2.5 mg Tablets, Arimidex® 1 mg film-coated tablets, Zoladex 10,8 mg implantat, Aromasil 25 mg comprimidos recubiertos, Verzenios 100 mg film-coated tablets, Zoladex 3,6 mg implantat, Kisqali 200 mg film-coated tablets, Lutrate Depot Mensual 3,75 mg polvo y disolvente para suspensión inyectable de liberación prolongada, Verzenios 50 mg film-coated tablets

    Ningbo Cancer Hospital

    Early Breast Cancer

    approved small molecule active

    1 trial

  9. METHADONE , Suboxone 2 mg/0.5 mg sublingual tablets

    Disc Medicine

    Opioid use disorder (DSM-5); chronic non-cancer pain (ICD-11).

    approved small molecule active

    1 trial

  10. MORPHINE , EDOXABAN , ENZALUTAMIDE

    Disc Medicine

    Prostate cancer

    approved small molecule active

    1 trial

  11. MedPulser Electroporation with bleomycin

    INOVIO PHARMACEUTICALS, INC.

    Cancer

    approved other completed

    1 trial

  12. Medpulser electroporation with Bleomycin

    INOVIO PHARMACEUTICALS, INC.

    Head and Neck Cancer

    approved other terminated

    2 trials

  13. Mekinist, DRB436, DRB436, TMT212, TMT212, Mekinist 0.5 mg film-coated tablets, DRB436, Mekinist 2 mg film-coated tablets

    Novartis Pharmaceuticals

    Children and Adolescents with Cancers Harboring V600 mutation.

    approved small molecule active

    1 trial

  14. Niraparib

    Takeda

    Epithelial Ovarian Cancer

    approved small molecule active

    1 trial

  15. OROS hydromorphone

    Janssen Cilag International NV

    Cancer Pain

    approved small molecule completed

    1 trial

  16. PEG-rhG-CSF

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cervical Cancer

    approved small molecule active

    1 trial

  17. Pegylated liposomal doxorubicin

    The First People's Hospital of Lianyungang

    Breast Cancer

    approved small molecule active

    1 trial

  18. Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Prostate cancer

    approved small molecule active

    1 trial

  19. RIBOCICLIB, Kisqali 200 mg film-coated tablets

    The George Institute

    Hormone receptor–positive (HRpos)/human epidermal growth factor receptor 2–negative (HER2neg) early breast cancer at risk of recurrence

    approved small molecule active

    1 trial

  20. Realgar-Indigo Naturalis Formulation Combined with Anlotinib

    The First People's Hospital of Lianyungang

    Platinum-resistant Ovarian Cancer (PROC)

    approved small molecule active

    1 trial

  21. Ribociclib

    Novartis Pharmaceuticals

    Metastatic Breast Cancer

    approved small molecule active

    1 trial

  22. S-1

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    approved small molecule active

    1 trial

  23. SELPERCATINIB, SELPERCATINIB

    Eli Lilly Co.

    Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration;

    approved small molecule active

    1 trial

  24. SIS-reinforced anastomosis

    Rocket Pharmaceuticals B.V.

    Rectal Cancer

    approved other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources